Welcome to our dedicated page for Apogee Therapeutics SEC filings (Ticker: APGE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Apogee Therapeutics, Inc. filings document a clinical-stage biotechnology issuer focused on antibody programs for inflammatory and immunology indications. The company’s Form 8-K disclosures cover operating results, Regulation FD clinical-data presentations for zumilokibart (APG777), APG279 and APG333 development activity, and material agreements related to public common-stock offerings.
Proxy materials cover annual meeting matters, director elections, board composition, executive compensation, equity awards and shareholder voting. The filings also identify APGE common stock on The Nasdaq Global Market and provide recurring capital-structure, governance, clinical or regulatory, and financial disclosures tied to the company’s research and development model.
Apogee Therapeutics, Inc. (APGE) is being acquired by AbbVie Inc. under an Agreement and Plan of Merger pursuant to which Andor Merger Co., a subsidiary of AbbVie, merged with and into Apogee on September 3, 2026, with Apogee surviving as a wholly owned subsidiary of AbbVie’s subsidiary Andor LLC.
At the effective time of the merger, each outstanding share of Apogee voting and non‑voting common stock (with specified exclusions) was cancelled and converted into the right to receive $135.11 in cash per share, subject to tax withholding. In-the-money stock options, restricted stock units, restricted stock and warrants were similarly cashed out based on this merger consideration, while out-of-the-money options were cancelled without payment. The reporting Venrock and related entities disposed of an aggregate 1,750,000 voting shares, 6,743,321 non‑voting shares, 365,853 pre‑funded warrants and options for 80,246 shares for this consideration and now report 0 shares and 0.0% beneficial ownership. Following the merger, Apogee’s common stock ceased trading on the Nasdaq Global Market before the open on September 4, 2026 and became eligible for delisting and deregistration under the Exchange Act.
Apogee Therapeutics, Inc. (APGE) reports in this Schedule 13D/A (Amendment No. 7) that its previously announced merger with Andor LLC, a wholly owned subsidiary of AbbVie Inc., was consummated on September 3, 2026. Andor Merger Co. merged with and into Apogee, with Apogee surviving as a wholly owned subsidiary of Andor LLC.
At the effective time, each share of Apogee common and non-voting common stock held by the reporting persons was cancelled and converted into the right to receive $135.11 per share in cash, and each stock option they held was cancelled for a cash amount equal to the excess of this merger consideration over the option exercise price. As a result, Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., Peter Evan Harwin and Tomas Kiselak now report 0 shares beneficially owned, representing 0.0% of the class, and a prior Voting Agreement relating to the securities automatically terminated.
Apogee Therapeutics, Inc. (APGE) reports that investment entities associated with Fairmount Funds and related directors disposed of their holdings in connection with a merger under which AbbVie Inc. is acquiring Apogee. All reported common and non-voting common shares, including 6,743,321 shares of non-voting common stock and 340,855 shares of common stock held through Fairmount Healthcare Fund II L.P., were transferred to the acquirer’s merger vehicle in exchange for cash of $135.11 per share. Vested stock options held for Fairmount-managed vehicles were also canceled for cash equal to $135.11 minus the applicable exercise price, and the Fairmount parties and the named individuals disclaim beneficial ownership except to the extent of any pecuniary interest.
Apogee Therapeutics, Inc. (APGE) director Mark C. McKenna reported dispositions of company securities in connection with a merger. On September 3, 2026, he returned vested stock options covering 150,000, 10,370, 14,461 and 7,657 shares of common stock to the issuer, with exercise prices of $23.60, $43.85, $41.66 and $85.00, respectively. Each option was cashed out under an Agreement and Plan of Merger at $135.11 per share of merger consideration, reduced by the relevant exercise price. In a related transaction, 20,000 shares of common stock were also disposed of pursuant to the same merger agreement, and his directly held common stock position became 0 shares after the transaction. The filing states that these options were vested or became fully vested in connection with the merger and that no Rule 10b5-1 trading plan is reported.
Apogee Therapeutics, Inc. (APGE) director William A. Jones Jr. reported the disposition of company equity in connection with a merger under an Agreement and Plan of Merger among Andor LLC, Andor Merger Co., Apogee Therapeutics, Inc. and AbbVie Inc. on September 3, 2026.
Jones disposed of 34,824 shares of common stock and three blocks of vested stock options covering 10,370, 14,461 and 7,657 shares. Each option was cashed out for the cash value of the per share merger consideration of $135.11 minus its exercise price, and Jones reported holding no shares of common stock directly after the transactions. No Rule 10b5-1 plan is reported.
Apogee Therapeutics, Inc. (APGE) reports that Chief Medical Officer Carl Dambkowski disposed of common stock and stock options in early September 2026, primarily in connection with the cash merger of Apogee with an AbbVie Inc.–affiliated entity under an Agreement and Plan of Merger.
Apogee Therapeutics, Inc. (APGE) reports that director Jennifer A. Fox disposed of her equity position in connection with a merger. On September 3, 2026, she transferred 34,824 shares of common stock to the company under an Agreement and Plan of Merger involving AbbVie Inc. and related entities, leaving her with no directly held common shares.
On the same date, three vested stock option awards covering 10,370 shares at an exercise price of $43.85, 14,461 shares at $41.66, and 7,657 shares at $85.00 were also disposed of to the issuer. Each option was cashed out for an amount equal to the $135.11 per share merger consideration minus the respective exercise price, consistent with the merger terms. No Rule 10b5-1 trading plan is reported for these transactions.
Apogee Therapeutics, Inc. (APGE) reported that Chief Financial Officer Jane Henderson disposed of company equity on September 3, 2026 in connection with a merger under an Agreement and Plan of Merger among Andor LLC, Andor Merger Co., Apogee Therapeutics, Inc. and AbbVie Inc. The transactions included the disposition of 158,371 shares of common stock, after which she held no shares of common stock directly. Three vested stock option awards covering 175,345, 124,962 and 83,690 underlying shares, with exercise prices of $22.86, $49.07 and $75.78 per share, respectively, were also disposed of in connection with the merger. Each option was cashed out for an amount equal to the excess of the $135.11 per share merger consideration over its exercise price, rather than exercised for shares. The options were vested as of, or became fully vested in connection with, the merger, and the filing does not state that these transactions were made under a Rule 10b5-1 trading plan.
Apogee Therapeutics, Inc. (APGE) director Lisa Bollinger reported the disposition to the issuer of four tranches of vested stock options on September 3, 2026 in connection with a merger. Options covering 18,550, 8,112, 14,461 and 7,657 shares of common stock, with exercise prices of $47.86, $43.85, $41.66 and $85.00 respectively, were canceled pursuant to an Agreement and Plan of Merger dated June 18, 2026. Each option was exchanged for a cash payment equal to the merger consideration of $135.11 minus its exercise price, and the filing states these options were vested or became fully vested in connection with the merger. No Rule 10b5-1 trading plan is reported.
Apogee Therapeutics, Inc. (APGE) reports that Chief Executive Officer and director Michael Thomas Henderson disposed of his equity interests in connection with a merger involving Andor LLC, Andor Merger Co. and AbbVie Inc. On September 3, 2026, he returned 920,941 shares of common stock to the issuer under the merger terms and three fully vested option grants were canceled in exchange for cash equal to the $135.11 per share merger consideration minus each option’s exercise price. No Rule 10b5-1 trading plan is reported for these transactions.